BioCentury
ARTICLE | Strategy

Prepping for PCSK9s

How Sanofi should think about pricing/rebates for first-to-market PCSK9 inhibitor

March 9, 2015 7:00 AM UTC

By securing Priority Review for Praluent alirocumab, Sanofi and Regeneron Pharmaceuticals Inc. deprived Amgen Inc. of what could have been a three-month head start with its competing PCSK9 inhibitor. But the partners also put themselves in the position of going first in what could be a game of chicken with payers.

Thanks to the use of a Priority Review voucher, the BLA for Sanofi and Regeneron's Praluent alirocumab to treat hypercholesterolemia has a July 24 PDUFA date. Amgen's PCSK9 inhibitor evolocumab has an Aug. 27 PDUFA date...